Ironwood Receives $75M from Astellas for IBS Drug
The Cambridge, Mass.-based company has signed a $75 million deal with Astella Pharmaceuticals to market Ironwood’s IBS drug in Asia.
feature2
Avanir Shares Rise on Zenvia Trial Data
Avanir, a pharmaceutical company developing treatments for CNS disorders and inflammatory diseases, announced that its multiple sclerosis drug Zenvia met its goal in a six-month clinical trial.
Bioniche Receives $6M Milestone Payment for Bladder Cancer Drug
Bioniche Life Sciences has received its first milestone payment of $6 million from Endo Pharmaceuticals for its experimental bladder cancer drug.
Guided Therapeutics Study Reveals Cervical Screening Shortcomings
A clinical trial by Guided Therapeutics (GT), a biotechnology company specializing in women’s health, found that current screening methods for cervical disease missed the disease nearly a third of the time.
GenVec Receives Orphan Drug Designation, $22M Development Deal
GenVec’s experimental drug to treat pancreatic cancer has been granted orphan drug status by the U.S. Food and Drug Administration.
UNICEF and WHO Launch Global Plan Against Pneumonia
The World Health Organization (WHO) and UNICEF are kicking off a comprehensive plan to fight the world’s leading child killer.
Micromet Signs $477M Deal with Sanofi-Aventis
Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.
Ligand to Buy Struggling Metabasis
Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
Cohera Receives Approval for Surgical Adhesive Trial
Pittsburgh-based Cohera Medical has received approval to begin clinical trials on its TissuGlu surgical adhesive in Europe.
Zogenix, Astellas Announce Positive Data for Unique Migraine Therapy
Zogenix, a pharmaceutical company specializing in the treatment of chronic pain, and Astellas Pharma have announced positive clinical trial data from two studies of their needle-free migraine treatment system.